National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree,

Slides:

Advertisements

Similar presentations

Su K. Metcalfe, MD, MPH, Michael T

Advertisements

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Sarah J. Gao, BS, Christopher D. Corso, MD, PhD, Elyn H

Melanie Subramanian, MD, Timothy McMurry, PhD, Bryan F

Evaluation of the Reliability of Clinical Staging of T2 N0 Esophageal Cancer: A Review of The Society of Thoracic Surgeons Database Traves D. Crabtree,

Endoscopic Ultrasound for Early Stage Esophageal Adenocarcinoma: Implications for Staging and Survival Traves D. Crabtree, MD, Wael N. Yacoub, MD, Varun.

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Does the method of radiologic surveillance affect survival after resection of stage I non– small cell lung cancer? Traves D. Crabtree, MD, Varun Puri,

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database Alex.

Paul J. Scheel, BS, Traves D. Crabtree, MD, Jennifer M

Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Brian N. Arnold, MD, Daniel C. Thomas, MD, MPH, Joshua E

Joshua E. Rosen, BASc, Michelle C

Serum Thymidine Kinase 1 Activity in the Prognosis and Monitoring of Chemotherapy in Lung Cancer Patients: A Brief Report Benjamin Nisman, PhD, Hovav.

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non–Small Cell Lung Cancer Treated with Stereotactic.

Varun Puri, MD, Andrew Tran, MS, Jennifer M. Bell, BS, Traves D

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Benefits of resection for metachronous lung cancer

Utility of mediastinoscopy in clinical stage I lung cancers at risk for occult mediastinal nodal metastases Felix G. Fernandez, MD, Benjamin D. Kozower,

A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.

Adjuvant Chemotherapy Is Associated With Improved Survival in Locally Invasive Node Negative Non-Small Cell Lung Cancer Usman Ahmad, MD, Traves D. Crabtree,

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Defining the Ideal Time Interval Between Planned Induction Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer Pamela Samson, MD, MPHS, Traves.

The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis Pamela Samson, MD, Aalok Patel, BS,

Quality Measures in Clinical Stage I Non-Small Cell Lung Cancer: Improved Performance Is Associated With Improved Survival Pamela Samson, MD, MPHS, Traves.

The National Surgical Quality Improvement Program risk calculator does not adequately stratify risk for patients with clinical stage I non–small cell.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Increasing Rates of No Treatment in Advanced-Stage Non–Small Cell Lung Cancer Patients: A Propensity-Matched Analysis Elizabeth A. David, MD, Megan E.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

Defining Optimal Comorbidity Measures for Patients With Early-Stage Non-small cell lung cancer Treated With Stereotactic Body Radiation Therapy Todd.

The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non–Small Cell Lung Cancer Eric D. Miller, MD,

Treatment Outcomes in Stage I Lung Cancer

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Yinin Hu, MD, Varun Puri, MD, Traves D

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Extent of Lymphadenectomy Is Associated With Improved Overall Survival After Esophagectomy With or Without Induction Therapy Pamela Samson, MD, MPHS,

Mara B. Antonoff, MD, Varun Puri, MD, Bryan F

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Daniel Kreisel, MD, PhD, Alexander S

Role of Postoperative Radiotherapy in Nonlocalized Thymoma

Office-Based Spirometry: A New Model of Care in Preoperative Assessment for Low- Risk Lung Resections Jessica L. Hudson, MD, MPHS, Jennifer M. Bell, BSN,

Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn.

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Genetic Changes in Squamous Cell Lung Cancer: A Review

Adhering to Quality Measures in Esophagectomy Is Associated With Improved Survival in All Stages of Esophageal Cancer Pamela Samson, MD, MPHS, Varun.

Stephen R. Broderick, MD, MPHS, Aalok P. Patel, BS, BA, Traves D

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Patterns of care in hilar node-positive (N1) non–small cell lung cancer: A missed treatment opportunity? Matthew J. Bott, MD, Aalok P. Patel, BS, Vivek.

Effects of Delayed Surgical Resection on Short-Term and Long-Term Outcomes in Clinical Stage I Non-Small Cell Lung Cancer Pamela Samson, MD, Aalok Patel,

Lobectomy versus stereotactic body radiotherapy for stage I non–small cell lung cancer: Post hoc analysis dressed up as level-1 evidence? Bryan F. Meyers,

Varun Puri, MD, Yinin Hu, MS, Tracey Guthrie, RN, Traves D

Liseth L. van den Berg, MD, Theo J. Klinkenberg, MD, Harry J. M

Treatment of Malignant Pleural Effusion: A Cost-Effectiveness Analysis

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Kalpaj Parekh, MD, Bryan F. Meyers, MD, G

Population-Based Patterns of Surgical Care for Stage IIIA NSCLC in the Netherlands between 2010 and 2013 Chris Dickhoff, MD, Max Dahele, MBChB., PhD,

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

National Patterns of Care and Outcomes After Combined Modality Therapy for Stage IIIA Non–Small-Cell Lung Cancer Aalok P. Patel, BS, Traves D. Crabtree, MD, Jennifer M. Bell, BSN, Tracey J. Guthrie, BSN, Clifford G. Robinson, MD, Daniel Morgensztern, MD, Graham A. Colditz, MD, DrPH, Daniel Kreisel, MD, PhD, A. Sasha Krupnick, MD, Jeffrey D. Bradley, MD, G. Alexander Patterson, MD, Bryan F. Meyers, MD, MPH, Varun Puri, MD Journal of Thoracic Oncology Volume 9, Issue 5, Pages 612-621 (May 2014) DOI: 10.1097/JTO.0000000000000152 Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Consort Diagram showing schema of study subject selection and analysis. Journal of Thoracic Oncology 2014 9, 612-621DOI: (10.1097/JTO.0000000000000152) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier survival of patients undergoing combination chemotherapy and radiation (CR) versus chemotherapy, radiation, and surgery (CRS). A, This is an unmatched comparison; (B) propensity score matched comparison; (C) this is an unmatched comparison; and (D) propensity score matched comparison. Journal of Thoracic Oncology 2014 9, 612-621DOI: (10.1097/JTO.0000000000000152) Copyright © 2014 International Association for the Study of Lung Cancer Terms and Conditions